GLP-1RA Therapy Recovers Vascular Regenerative Cell Content in High Cardiovascular-Risk Individuals with Type 2 Diabetes

被引：0
|
作者：
Krishnaraj, Aishwarya
Park, Brady
Bakbak, Ehab
Verma, Raj
Quan, Adrian
Teoh, Hwee
Hess, David A.
Verma, Subodh
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-755-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
755-P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?
    Bai, Shuzhen
    Lin, Chu
    Jiao, Ruoyang
    Cai, Xiaoling
    Hu, Suiyuan
    Lv, Fang
    Yang, Wenjia
    Zhu, Xingyun
    Ji, Linong
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 109 : 79 - 88
  • [22] Health Care Utilization and Cost with Empagliflozin vs. GLP-1RA in Patients with Type 2 Diabetes
    Htoo, Phyo T.
    Tesfaye, Helen
    Wexler, Deborah J.
    Glynn, Robert
    Schmedt, Niklas
    Koeneman, Lisette
    Paik, Julie M.
    Patorno, Elisabetta
    DIABETES, 2024, 73
  • [23] PROVIDER-REPORTED BARRIERS TO GUIDELINE-DIRECTED UTILIZATION OF SGLT2I/GLP-1RA AGENTS AMONG PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK FOR CARDIOVASCULAR DISEASE
    Qian, Frank
    Chaudhary, Richard
    Jonas, Zachary
    Ward, Charlotte
    Moran, Sara
    Quadir, Juweria
    Chen, Zsu-Zsu
    Benson, Mark D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1887 - 1887
  • [24] Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
    Andreasen, Christine Rode
    Andersen, Andreas
    Knop, Filip Krag
    Vilsboll, Tina
    DIABETES OBESITY & METABOLISM, 2021, 23 : 40 - 52
  • [25] Real-World Adherence and Discontinuation of GLP-1 Receptor Agonist (GLP-1RA) Therapy in Type 2 Diabetes (T2D) Patients in the US
    Weiss, Tracey
    Iglay, Kristy
    Carr, Richard D.
    Mishra, Ajay Pratap
    Yang, Lingfeng
    Rajpathak, Swapnil
    DIABETES, 2019, 68
  • [26] GLP-1 RA and Risk of Malignancy in Patients with Type 2 Diabetes
    Ishola, Faidat A.
    Pike, C. William
    Kim, Sun H.
    DIABETES, 2024, 73
  • [27] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
    Hiep Nguyen
    Robert Dufour
    Amanda Caldwell-Tarr
    Advances in Therapy, 2017, 34 : 658 - 673
  • [28] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
    Nguyen, Hiep
    Dufour, Robert
    Caldwell-Tarr, Amanda
    ADVANCES IN THERAPY, 2017, 34 (03) : 658 - 673
  • [29] Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial
    Haff, Nancy
    Horn, Daniel M.
    Bhatkhande, Gauri
    Sung, Meekang
    Colling, Caitlin
    Wood, Wendy
    Robertson, Ted
    Gaposchkin, Daniel
    Simmons, Leigh
    Yang, Judy
    Yeh, James
    Crum, Katherine L.
    Hanken, Kaitlin E.
    Lauffenburger, Julie C.
    Choudhry, Niteesh K.
    AMERICAN HEART JOURNAL, 2025, 285 : 39 - 51
  • [30] Impact of GLP-1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol-Associated Liver Disease and Type 2 Diabetes
    Rashid, Zayed
    Woldesenbet, Selamawit
    Khalil, Mujtaba
    Iyer, Sidharth
    Khan, Muhammad Muntazir Mehdi
    Altaf, Abdullah
    Munir, Muhammad Musaab
    Catalano, Giovanni
    Mumtaz, Khalid
    Pawlik, Timothy M.
    LIVER INTERNATIONAL, 2025, 45 (04)
12345